iRGD as a tumor-penetrating peptide for cancer therapy (Review)

HONG YIN1,2*, JIE YANG1*, QING ZHANG1, JIE YANG1,2, HAIYU WANG1, JIN JING XU1 and JUNNIAN ZHENG1,3,4

1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002; 2Center of Radiotherapy of The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221006; 3The Cancer Center of The Affiliated Hospital of Xuzhou Medical University; 4Jiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China

Received January 27, 2016; Accepted January 23, 2017

DOI: 10.3892/mmr.2017.6419

Abstract. As a tumor-targeting and -penetrating peptide, iRGD binds to αv integrins and neuropilin-1 receptors, which are expressed at high levels on tumor cells and the surfaces of vasculature. Subsequently, iRGD penetrates deep into the tumor parenchyma with antitumor drugs, imaging agents, immune modulators and biological products. These substances are either chemically linked to the peptide or co-injected with the peptide. The iRGD peptide can be readily synthesized, exhibits significantly improved penetration, compared with traditional peptides, and can effectively inhibit tumor metastasis. Therefore, the peptide is now used widely for the diagnosis and treatment of cancer. However, whether the peptide is able to promote the entry of drugs into non-targeted cells remains to be fully elucidated. In this review, an overview of iRGD is presented, focusing on its identification, mechanism of action and previous studies on its roles in various types of cancer. Studies in previous years have demonstrated the potential of the iRGD protein for tumors diagnosis and targeted treatment, which warrants further investigation.

Contents

1. Introduction
2. Initial peptide identification
3. Mechanism of iRGD penetration
4. iRGD for tumor diagnosis and treatment
5. Conclusion

1. Introduction

Cancer is a global health problem, and is gradually becoming the primary contributor to mortality rates in women and men in developing and developed countries (1). In previous years, chemotherapy, radiotherapy, surgery and immunotherapy have been the primary treatment methods for cancer (2). Chemotherapy has always been considered the principle and most common method, however, it exhibits drawbacks, including the low concentration of chemotherapeutic drug at the tumor site, and serious side effects due to chemotherapeutic drugs not specifically targeting tumors and always affecting normal cells/tissues. Furthermore, chemotherapeutic drugs only possess a limited capacity to penetrate into the parenchyma of solid tumors. Due to these limitations, improving the efficiency of chemotherapeutic drugs is an urgent requirement (3,4).

As drugs for the treatment of solid tumors can only penetrate 3-5 cell diameters from blood vessels (5), the low concentration of anticancer drugs at the tumor site is a substantial obstacle for tumor treatment, which limits the anticancer efficacy and suggests that the effective drug concentration at the tumor site is markedly lower, compared with the dose of exposure. In previous decades, cancer studies have focused on tumor-targeting peptides, which support drug penetration. Conventional RGD-peptides bind selectively to integrins αvβ3 and αvβ5, which are excessively expressed on several types of tumor (6). These peptides successfully deliver drugs, nanoparticles, viruses and biologicals to the blood vessels (7), and marginally increase accumulation within the tumor, however, their limited loading capacity in the tumor parenchyma remains a challenge for cancer therapy.

In previous years, improved novel peptides aimed at identifying tumor blood vessels and tumor cells appear to be more effective in the treatment of tumors, compared with traditional penetrating peptides (7,8). The iRGD (CRGDKGPDC) peptide has been developed on the basis of RGD peptides and is composed of nine amino acids. It first binds to αv integrins, which are expressed on tumor cells and vessels. Subsequently, it is cleaved by proteases to expose the neuropilin-1 (NRP-1)-binding CRGDK/R, which effectively
triggers the tumor penetration process (7,9). The peptide is used to increase the pore diameter and surface area of tumor blood vessels, and to reduce the pressure effect in the tumor interstitium, increasing the rate of diffusion of small molecule drugs (10-12). The scientific interest in iRGD has resulted from its binding to NRP-1 in particular, as this triggers extravasation (13). Furthermore, iRGD specifically penetrates into angiogenic vessels and tumor tissues. Due to this novel delivery system and the low toxicity to normal cells, iRGD has attracted significant attention (14). Further advantages of iRGD arise from its simple and low-cost synthesis. Coupled with iRGD, drugs, nanoparticles and proteins can be effectively delivered to the tumor site, which reduces side effects. At present, the iRGD peptide is widely used in the diagnosis and treatment of tumors.

2. Initial peptide identification

The tumor vasculature is indispensable in the process of tumor growth and metastasis, as it not only provides the tumor with the necessary nutrients and oxygen, but also assists in the transportation of cancer cells to adjacent or distant organs for tumor metastasis (15). Therefore, the tumor vasculature can be considered as the target of tumor diagnosis and treatment. Phage peptides, first identified by Pasqualini and Ruoslahti in 1996, have been widely used (16). The homing peptide on the phage coat protein combines with target molecules in vascular endothelial cells. A mass screening of the phage allows for the selective detection of targeted phage peptides, which combine into tumor blood vessels (17-19). Using this method, an increasing number of peptides targeting the tumor vasculature can be identified. Substantial experimental data have shown that these peptides can deliver drugs to tumors and act as effective image contrast agents (20,21), thus are important in tumor diagnosis and treatment. RGD and NGR are the two most well-known short peptides targeting tumor vasculature in phages. iRGD has been developed as a novel type of tumor-penetrating peptide, which not only targets tumor blood vessels, but can also deliver drugs deep into the tumors. The iRGD peptide results from the connecting of RGD with NRP-1 peptide ligands. iNGR was designed based on known sequence elements (22).

3. Mechanism of iRGD penetration

The RGD sequence (Arg-Gly-Asp) selectively binds to αβ3 and αβ5 integrins which are overexpressed in the tumor vasculature (23). Further studies have shown that connecting the peptide ligands of NRP-1 and RGD improves drug delivery to the extravascular tissues in addition to the tumor blood vessels. The target peptide CendR, can only be activated when the C-terminus of the motif is exposed. Subsequently, the activated CendR can bind to NRP-1, which is expressed at high levels on tumor tissues, to initiate deep tissue penetration (8). In general, iRGD acts through the following steps: RGD peptides bind to αβ3 and αβ5 integrins on tumor cells and tumor blood vessel endothelial cells. Secondly, under the action of cellular proteases, the peptide is cleaved to expose the activated CendR motif at the C-terminus. Finally, CendR binds to NRP-1, which triggers tumor tissue penetration carrying the cargo at the N-terminus (Fig. 1).

4. iRGD for tumor diagnosis and treatment

**iRGD in tumor preclinical diagnosis.** In 2009, Sugahara et al intravenously infused iRGD-linked iron oxide nanoworms into tumor-burdened mice. A low MRI signal intensity was detected in the entire tumor, which was confirmed using MRI imaging. Therefore, the detection methods consistently indicated the superiority of iRGD over the RGD peptide in terms of its ability to transfer diagnostic agents to tumors (7). In 2011, Ye et al synthesized the two near-infrared fluorescence-labeled iRGD peptides, Ac-Cys (IRDye800CW)-iRGD and DOTA-Cys (IRDye800CW)-iRGD. These peptides were injected intravenously into mice bearing MDA-MB-435 tumors, which revealed the tumor locations (24). In 2015, iRGD-modified porous silicon nanoparticles were verified for cancer theranostics through *in vitro* and *in vivo* experiments (25). This revealed the potential of the iRGD peptide as a diagnostic reagent in clinical practice.

**iRGD mediates drug delivery for cancer treatment.** The mode of action of iRGD is well understood and its preclinical application is developing widely. Substantial investigations have been performed to investigate the application of iRGD as an antitumor agent *in vitro* and *in vivo*, which are briefly summarized in the following.

Sugahara et al (26) reported that co-injection with iRGD enhances the antitumor effect of free drugs without a chemical entity, and reduced the side effects of drugs in mice bearing five tumors, including human breast cancer, prostate cancer and pancreatic adenocarcinoma. Investigations have revealed the simplicity and effectiveness of the co-injection of iRGD and tumor-targeting drugs. This combination does not alter the chemical structure of the drugs, thus avoiding structural alterations, which may reduce the activity of the functional drugs. These findings also encourage the co-administration of iRGD in various forms of drug applications for future investigations in the treatment of different types of tumor. Sugahara et al also reported that iRGD effectively improved the curative effect of doxorubicin (DOX) in inhibiting peritoneal carcinomatosis. It was confirmed that the intratumoral aggregation of intra-peritoneally co-injected DOX in mice was ~1.5 times higher. Based on this finding, it was concluded that intraperitoneally co-administered iRGD can be regarded as a simple and effective way to inhibit the progression of peritoneal carcinomatosis and improve the effect of chemotherapy (26).

In studies involving transplantation models, cisplatin (CDP) was co-administered with iRGD resulting in an increase in survival rates by 30% and a substantial reduction in the toxicity of the chemotherapeutic drugs (27).

In 2013, Gu et al associated iRGD with paclitaxel-loaded nanoparticles for drug delivery to the C6 glioma parenchyma. Mice bearing C6 glioma cells, which were treated with the iRGD-associated nanoparticles, had markedly increased survival rates, compared with the mice, which had not received the iRGD-associated treatment (28).

iRGD has also been selected as a targeting ligand and has been used for the modification of sterically-stabilized
luposomes (SSLs). Chemotherapeutic drugs (CLA-PTX or DOX) were loaded to these liposomes to yield iRGD-SSL-CLA-PTX or iRGD-SSL-DOX, which were assessed in C57BL/6 mice bearing B16-F10 tumors, respectively. The results showed that the tumor volumes were significantly reduced upon iRGD-SSL-CLA-PTX or iRGD-SSL-DOX treatment, compared with tumors in mice, which had not received the corresponding iRGD modification (29,30).

For the efficient delivery of the DOX-polymer to tumor tissues, Wang et al. synthesized an iRGD-PPCD conjugate, which was injected intravenously into mice with subcutaneously implanted C6-glioma-tumors. These *in vivo* investigations showed that iRGD-PPCD has a superior penetrating capacity, compared with RGD. Statistical analysis revealed that the median duration of survival of the mice following treatment with iRGD-mediated drugs was longer, compared with that following treatment with RGD-mediated drugs, indicating that iRGD improved the antitumor effect and penetration efficacy (31).

Akashi et al. developed pancreatic cancer models. They treated tumor-burdened nude mice with a combination of gemcitabine (GEM) and iRGD, and observed prominent tumor reduction, compared with mice treated with GEM only in the cell line-based xenografts (32).

Derived from the anti-apoptotic protein, Bfl-1, amphipathic tail-anchoring peptide (ATAP) is used as a mitochondrial targeting peptide. The ATAP modifications, ATAP-iRGD-M8 and ATAP-iRGD exhibit improved stability and solubility, and improved capacity in selective delivery to tumor tissues. The two peptides significantly decreased tumor sizes in nude mice burdened with DU145 and PC3 cells (14).

Puig-Saas et al. (33) inserted iRGD into an oncolytic adenovirus to increase adenovirus penetration to the tumor mass. By inserting the peptide, nude mice bearing subcutaneous A549 and MIA PaCa-2 xenograft tumors showed improved tumor growth control, compared with mice without iRGD, and extended mean survival rates. These findings effectively demonstrated that the iRGD peptide enhances transduction, intratumoral dissemination and adenovirus infiltration into the tumor parenchyma to exert an antineoplastic effect (26,33).

Porous silicon (PSi) has been coupled with iRGD as a drug delivery carrier. The final sorafenib-loaded PSi-iRGD has shown a more marked antitumor effect *in vitro*, which again confirmed the above-described effect of iRGD (34).

Epidermal growth factor receptors (EGFRs), which are closely associated with the prognosis of cancer, are expressed at high levels on the surfaces of different human tumor cells, including gastric cancer and gastric lung cancer. It has been reported that anti-EGFR-iRGD, a composite protein targeting αvβ3, αvβ5, NRP-1 and EGFRs, shows potent tumor tissue penetration ability. *In vivo* investigations of mice bearing subcutaneous BGC-823, which received intraperitoneal injections, showed that the combination of DOX with anti-EGFR-iRGD was more effective at inhibiting BGC-823 MCS growth, compared with chemotherapeutic drugs (35).

A report in 2015 described the co-administration of DOX-loaded, CDDP-crosslinked and polysaccharide-based nanoparticles (Dex-SA-DOX-CDDP) with iRGD, afford marked advantages in inhibiting the tumor growth and metastasis of murine colorectal carcinoma and metastatic mammary carcinoma, compared with the corresponding nanoparticles without iRGD co-administration (36). Peng and Kopeček conjugated matrix metalloproteinase-2 with iRGD, and the resulting novel tumor-penetrating peptide conjugates exhibited the highest cytotoxicity towards DU-145 cells, which prompted further investigation (37). Zhang et al. established a human non-small cell lung cancer xenograft nude mice model with A549 cells. Treatment comprising a combination of GEM and iRGD was applied, which inhibited the growth of tumors, which were not sensitive to the same dose of GEM alone. Apoptotic cells in the tumor tissues were detected using a TUNEL assay and the statistical analysis revealed that the highest apoptotic index was for the groups treated with the GEM/iRGD combination (38).

Wang et al. demonstrated that iRGD-modified nanoparticles improved the tumor absorption of nanoparticles when injected intravenously. Intratumor injection confined the nanoparticles to the tumor to a greater degree, compared with the free drug (25). This study revealed another application of the iRGD peptide.
iRGD mediates biological product delivery for cancer treatment. In addition to chemotherapeutic drugs, Lao et al introduced the iRGD peptide sequence into the C-terminus of the thymopoietin pentapeptide, TP5, to improve the poor penetration ability of TP5. The findings suggested that the injections of TP5-iRGD inhibited melanoma progression more effectively, compared with the native peptide. In addition, computational observations of the mechanism of activity confirmed the potential of the peptide for tumor therapy (39).

Chen et al reported that the cell death domain (CDD) was effective for inducing cell apoptosis, therefore, CDD was fused to iRGD to obtain a tissue-penetrating protein. By injecting the protein intratumorally into mice bearing orthotopically-implanted MCF-10CA1a breast tumors, CDD-iRGD inhibited the growth of tumors, with a decrease in the tumor volumes by 77% (40). These studies reflect potential applications of iRGD coupled with biological products. The conjugation of iRGD with DSPE-PEG (2000) nanomicelles to yield M-SAL-iRGD also exhibited a prominent increase in cytotoxicity in cancer stem cells and liver cancer cells (41) (Table I).

iRGD inhibits metastasis. Metastasis is the primary cause of cancer-associated mortality, and studies have focused increasingly on the development of methods for improving resistance and treating cancer metastasis. The iRGD peptide itself does not affect the survival of cells (42), however, it has been reported to inhibit the metastasis of tumors.

As a tissue-penetrating peptide, iRGD efficiently delivers drugs and biological products to various tumors in rodent models. In 2015, Sugahara et al suggested that the iRGD peptide also spontaneously inhibits tumor metastasis, which was confirmed experimentally. Depending on NRP-1, iRGD inhibits spontaneous tumor metastasis, but has no effect on the size of primary tumors. Sugahara et al demonstrated this by developing nude mice models via the orthotopic transplantation of GFP-PC-3 and LM-PmC cells, which led to spontaneous metastases in different organs. The peptide was then injected intravenously into the tumor-bearing mice and circulated for 1 h. Based on the analysis of a series of in vivo and in vitro experiments, it was confirmed that the iRGD peptide inhibited tumor cells migration (42).

In 2015, Hamilton et al reported that iRGD nanoparticles significantly inhibited tumor development as long as they were applied in the early metastatic phase of tumor progression (43). Ni et al confirmed that only decorated nanocrystallites achieved complete intratumoral transfer and accessed cancer stem cells in the murine model, leading to the inhibition of 4T1 proliferation and metastasis (44).

5. Conclusion

iRGD consists of two motifs: The RGD motif, which binds to αv integrins aiming to target drugs accumulated in tumor tissues, and the CendR motif, which binds to NRP-1 to effectively inhibit tumor metastasis. In combination with contrast agents, chemotherapeutic drugs, nanoparticles or proteins, the iRGD peptide can be effectively delivered to the tumor site, reduce the side effects of drugs and improve the curative efficacy of drugs. In previous years, the application of the iRGD peptide for cancer diagnosis and therapy was assessed in pre-clinical in vivo and in vitro experiments, revealing promising results for tumor treatment. In addition to the progress in phage library technology and the development of new screening technologies, the iRGD tumor-tissue-penetrating peptide is likely to be more widely applied in the clinical diagnosis and treatment of tumors.

Table I. iRGD as a carrier applied in tumor treatment.

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Load carried by iRGD</th>
<th>Tumor</th>
<th>(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sugahara et al, 2010</td>
<td>DOX</td>
<td>Peritoneal carcinomatosis</td>
<td>(26)</td>
</tr>
<tr>
<td>Song et al, 2012</td>
<td>CDDP</td>
<td>A549</td>
<td>(27)</td>
</tr>
<tr>
<td>Du et al, 2014</td>
<td>iRGD-SSL-CLA-PTX</td>
<td>B16-F10</td>
<td>(29)</td>
</tr>
<tr>
<td>Yu et al, 2013</td>
<td>iRGD-SSL-DOX</td>
<td>B16-F10</td>
<td>(30)</td>
</tr>
<tr>
<td>Wang et al, 2014</td>
<td>Paclitaxel, iRGD-PPCD</td>
<td>C6 glioma</td>
<td>(31)</td>
</tr>
<tr>
<td>De et al, 2014</td>
<td>ATAP-iRGD-M8</td>
<td>DU145 and PC3</td>
<td>(14)</td>
</tr>
<tr>
<td>Sugahara et al, 2010; Puig-Saus et al, 2014</td>
<td>Oncolytic adenovirus</td>
<td>A549 and MIA PaCa-2</td>
<td>(26,33)</td>
</tr>
<tr>
<td>Sha et al, 2015</td>
<td>Dex-anti-EGFRs</td>
<td>BGC-823</td>
<td>(35)</td>
</tr>
<tr>
<td>Li et al, 2015</td>
<td>Dex-SA-DOX-CDDP</td>
<td>Colorectal carcinoma</td>
<td>(36)</td>
</tr>
<tr>
<td>Zhang et al, 2015</td>
<td>Gemcitabine</td>
<td>A549</td>
<td>(38)</td>
</tr>
<tr>
<td>Lao et al, 2014</td>
<td>Thymopoietin pentapeptide</td>
<td>Melanoma</td>
<td>(39)</td>
</tr>
<tr>
<td>Chen et al, 2013</td>
<td>Cell death domain</td>
<td>MCF-10CA1a</td>
<td>(40)</td>
</tr>
<tr>
<td>Mao et al, 2015</td>
<td>M-SAL</td>
<td>Cancer stem cells</td>
<td>(41)</td>
</tr>
</tbody>
</table>

DOX, doxorubicin; CDDP, cisplatin; PPCD, PEGylated-polyamidoamine-cis-aconityl-DOX; SSL, sterically stabilized liposome; ATAP, anti-apoptotic peptide; EGFRs, epidermal growth factor receptors; M-SAL, DSPE-PEG (2000) nanomicelles-salinomycin.
It is noteworthy that the iRGD peptide was investigated in a mouse model with subcutaneously transplanted tumors, whereas tumor xenograft models did not actually imitate the complex microenvironment of the cancer cells originated from the organ. Therefore, the interpretation of experimental results can have significant limitations. The microenvironment is important for balancing the factors of promoting angiogenesis and anti-angiogenesis, which determine the heterogeneity of angiogenesis in tumors (45). Studies, including a study by Hoffman et al (46-48) independently confirmed that tumor-penetrating peptides are important in an aneuploid model with orthotopically-transplanted tumors.

A variety of inflammatory cells, including lymphocytes, neutrophils and macrophages, infiltrate the tumor microenvironment and can secrete different types of cytokines, including growth factors and chemokines (49). Almost all of these inflammatory mediators are involved in tumor angiogenesis. Chronic inflammation is usually accompanied by regeneration and angiogenesis, which may increase the risk of certain types of cancer. Based on reports that tumors and inflammatory tissues have certain biomarkers in common, it is likely that tumor blood vessel-targeted peptides are also combined in the vessels of inflammatory diseases, similar to inflammation being associated with the formation of blood vessels. Lahdenranta et al (50) reported that RGD and NGR can be combined into the vessels of hypoxia-induced retinopathy and Buehler et al (51) indicated that the two peptides target the blood vessels of ischemic hearts. These findings further increase the scope of possible applications of the tumor-penetrating peptide, iRGD.

In conclusion, the iRGD peptide interacts with integrin and its ligand, has promising application prospects, and identifies tumors early for diagnosis and treatment. iRGD can be combined with chemical drugs, immune modulators and cytokines to effectively penetrate tumors, and exert more marked anti-angiogenic effects. The effect of the peptide has been confirmed by a substantial number of animal experiments, confirming significant effects and minimal side effects. Therefore, iRGD offers promise for improving the treatment of tumors in humans. However, for final application in cancer treatment, iRGD requires further investigation and successful outcomes in clinical trials.

Acknowledgements

This review was supported by grants from the Nature Science Foundation of China (grant no.81301946), the China Postdoctoral Science Foundation Funded Project (grant nos. 2013M540467 and 53470135), the Nature Science Foundation of Jiangsu Province (grant no. BK2012146) and the Jiangsu Provincial Office of Education Foundation (grant no. JHB2012-34).

References


